Author Correction: Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study

Ítems similars

• Author Correction: Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study
  per: Filipa Lynce, et al.
  Publicat: (2024-05-01)
• Serum analytes as predictors of disease recurrence and the duration of invasive disease-free survival in patients with triple negative breast cancer enrolled in the OXEL trial treated with immunotherapy, chemotherapy, or chemoimmunotherapy
  per: Renee N Donahue, et al.
  Publicat: (2025-04-01)
• How I treat HER2-low advanced breast cancer
  per: Ilana Schlam, et al.
  Publicat: (2023-02-01)
• A phase I trial of palbociclib and bosutinib with fulvestrant in patients with metastatic hormone receptor positive and HER2 negative (HR+ HER2-) breast cancer refractory to an aromatase inhibitor and a CDK4/6 inhibitor
  per: Tina Roy, et al.
  Publicat: (2023-06-01)
• Phosphoflow cytometry to assess cytokine signaling pathways in peripheral immune cells: potential for inferring immune cell function and treatment response in patients with solid tumors
  per: Nicole J. Toney, et al.
  Publicat: (2023-09-01)